Information updates

Third COVID-19 vaccine dose recommended for people who are severely immunocompromised

The Australian Technical Advisory Group on Immunisation (ATAGI) has released a statement, prepared in consultation with ASCIA, which recommends a third primary dose of COVID-19 vaccine for people who are severely immunocompromised. This includes people with primary immunodeficiencies (PID). The ATAGI statement is available at:

https://www.health.gov.au/news/atagi-statement-on-the-use-of-a-3rd-primary-dose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised

The following ASCIA documents have been updated to include the ATAGI recommendations:

The recommended interval for the third dose is two to six months after the second dose of vaccine. People with PID who had a second dose more than six months ago should receive a third dose whenever this is feasible.

In summary the ATAGI recommendations state that a third primary dose of the COVID-19 vaccine is recommended for people with the following immunocompromising conditions and/or therapies:

  • Primary immunodeficiency (PID) including combined immunodeficiency and syndromes, major antibody deficiency (e.g. common variable immune deficiency (CVID) or agammaglobulinemia), defects of innate immunity (including phagocytic cells), defects of immune regulation, complement deficiencies and phenocopies of primary immunodeficiencies.
  • Some immunosuppressive therapies.
  • Haematopoietic stem cell transplant (HSCT) recipients or chimeric antigen receptor T-cell (CAR-T) therapy within 2 years of transplantation.
  • Solid organ transplant with immunosuppressive therapy.
  • Active haematological malignancy.
  • Non-haematological malignancy with current active treatment excluding immunotherapy with immune checkpoint inhibitors.
  • Advanced or untreated HIV with CD4 counts <250/μL or those with a higher CD4 count unable to be established on effective antiretroviral therapy.
  • Long term haemodialysis or peritoneal dialysis.

ASCIA will continue to provide advice to ATAGI on the use of COVID-19 vaccines in people who are severely immunocompromised. 

ASCIA will also continue to update ASCIA COVID-19 information as recommendations and restrictions evolve.

In anticipation of lockdowns easing the following updated pictorial checklist has been developed, which is included in the COVID-19 and Immunodeficiency FAQ:

The following ASCIA COVID-19 information has also been recently updated, to include the Moderna Spikevax vaccine:

 

 

Mod ASCIA Member
Donate to AIFA
go to NAS website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.